Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary...
The crypto price crash has led to continued trouble for crypto stocks.
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February...
New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary...
Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease
Cathie Wood bets on Broadcom while shorting major market names in a week of activity.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune...
The famous congressional portfolio is rotating capital into dividend-paying financial stocks while doubling down on artificial intelligence and energy.
Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology
Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration...